Remibrutinib in Real-world Clinical Practice - a Germany Sub-study (REASSERT)

Inclusion Criteria

• •1. Patients with a confirmed diagnosis of primary CSU by the treating physician.
• •2. Aged at least 18 years on the date of enrollment.
• •3. Written informed consent of the patient to participate in the study and willingness to complete full follow-up period of 24 months.
• •1. Cohort 2: Inadequate control of CSU despite licensed dose or escalated sgH1-AH(s) (no other pre-treatment with exception of first generation H1-AH permitted) with decision (independent of study enrollment) to switch to remibrutinib treatment as per local label.
• •2. Cohort3: Any other treatment received in addition to H1-AH, any time during patients' CSU treatment history, with decision (independent of study enrollment) to switch to remibrutinib treatment as per local label. Note, occasional steroid rescue medication is out of scope for cohort definition. If a patient had been on continuous steroids for at least 3 weeks during treatment history, they will be included in cohort 3.